-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
-
Summary
-
Vanda Pharmaceuticals Inc. quarterly/annual Deferred Income Tax Expense (Benefit) history and growth rate from Q1 2019 to Q1 2024.
- Vanda Pharmaceuticals Inc. Deferred Income Tax Expense (Benefit) for the quarter ending March 31, 2024 was -$246K, a 112% decline year-over-year.
- Vanda Pharmaceuticals Inc. annual Deferred Income Tax Expense (Benefit) for 2023 was -$1.29M, a 214% decline from 2022.
- Vanda Pharmaceuticals Inc. annual Deferred Income Tax Expense (Benefit) for 2022 was $1.13M, a 83.2% decline from 2021.
- Vanda Pharmaceuticals Inc. annual Deferred Income Tax Expense (Benefit) for 2021 was $6.75M, a 8.98% increase from 2020.
Deferred Income Tax Expense (Benefit), Quarterly (USD)
Deferred Income Tax Expense (Benefit), YoY Quarterly Growth (%)